ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
出版年份 2016 全文链接
标题
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
作者
关键词
-
出版物
Expert Review of Neurotherapeutics
Volume 16, Issue 6, Pages 601-614
出版商
Informa UK Limited
发表日期
2016-04-05
DOI
10.1080/14737175.2016.1174577
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
- (2015) Robert E. Davis et al. PSYCHOPHARMACOLOGY
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
- (2015) Christoph U. Correll et al. World Psychiatry
- Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study
- (2015) Christoph U. Correll et al. World Psychiatry
- Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
- (2014) Maren Carbon et al. CNS SPECTRUMS
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
- (2014) Peng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis
- (2013) Giulio Scigliano et al. CNS DRUGS
- 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders
- (2013) Tiago A Mestre et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Reviewing the ketamine model for schizophrenia
- (2013) Joel Frohlich et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
- (2013) Stephen R. Marder et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
- (2013) John M. Kane et al. World Psychiatry
- Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
- (2012) Larry Alphs et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration
- (2012) Ni A. Khin et al. JOURNAL OF CLINICAL PSYCHIATRY
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Stephen S Lim et al. LANCET
- Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
- (2011) Herbert Y. Meltzer et al. AMERICAN JOURNAL OF PSYCHIATRY
- Serotonin 2A receptor antagonists for treatment of schizophrenia
- (2011) Bjørn H Ebdrup et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia
- (2011) Ira D. Glick et al. JOURNAL OF CLINICAL PSYCHIATRY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Increased Serotonin 2A Receptor Availability in the Orbitofrontal Cortex of Physically Aggressive Personality Disordered Patients
- (2010) Daniel R. Rosell et al. BIOLOGICAL PSYCHIATRY
- From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
- (2010) C.U. Correll EUROPEAN PSYCHIATRY
- Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
- (2010) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
- (2009) Christoph U. Correll JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
- (2009) O. D. Howes et al. SCHIZOPHRENIA BULLETIN
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More